Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...
Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...
The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.
Researchers have identified a range of genetic alterations that may lead to resistance to KRAS G12C inhibitors in patients ...
CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...
Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...
Anocca has achieved regulatory approval for its first clinical trial, VIDAR-1, a major milestone in the company’s transition ...
7d
News-Medical.Net on MSNBreakthrough drug combination targets KRAS mutation in lung cancerA breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have uncovered a powerful combination therapy leveraging sotorasib-an FDA-approved ...
Initial validation using orthotopic models: SIL204 administered subcutaneously (systemically) showed significant efficacy in ...
ALTA3263 is a potential best-in-class KRAS-selective small molecule inhibitor that potently targets >90% of KRAS mutations ALTA3263 is designed for complete KRAS target coverage, which will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results